Please ensure Javascript is enabled for purposes of website accessibility

Shares of Incyte Corporation Plummeted in January -- Here's Why

By Sean Williams – Feb 7, 2016 at 7:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A midstage trial for Incyte came to a grinding halt in January, but the company may have a far bigger concern to contend with down the line.

INCY Chart

What: Shares of Incyte (INCY 3.17%), a drug developer primarily focused on the development of therapies to treat cancer, plummeted to the tune of 35% in January based on data from S&P Capital IQ. The culprits for the drop were overall market sentiment and a stopped midstage study.

So what: As a whole, the biotech industry was taken to the woodshed in January. The Nasdaq Biotechnology Index wound up plunging 21% as investors ran for cover from companies that are losing money and burning cash. Instead, investors sought the protection of dividend-paying, low-volatility names in the utility and consumer discretionary sectors. The result was biotech stocks were hammered, with Incyte no exception.

However, the fundamental reason behind Incyte's shellacking in January can be traced to a press release after the closing bell on Jan. 27. The announcement was designed to inform shareholders that the combination of ruxolitinib (known commercially as Jakafi) and regorafenib (known commercial as Stivarga) was not performing to expectations in a midstage trial for patients with metastatic colorectal cancer and high C-reactive protein. A planned interim analysis of the phase 2 study showed that the combo was unlikely to meet the required efficacy to warrant completing the trial.

The concern here is that Incyte's only approved product, Jakafi, a JAK1/JAK2 inhibitor, is being tested in multiple other cancer types, including a pivotal pancreatic cancer study, as well as proof-of-concept trials in breast cancer and lung cancer. The failure of Jakafi to deliver meaningful efficacy in phase 2 studies certainly could cloud its future in cancer treatment beyond myelofibrosis and polycythemia vera, its two approved indications.

Following this announcement, six separate investment firms cut their price targets on Incyte. 

Image source: Incyte.

Now what: Personally, I believe there are far bigger worries for Incyte than just its shelved metastatic colorectal cancer combo study. It has Geron (GERN 1.92%) nipping at its heels with imetelstat, and it's possible Incyte could surrender its myelofibrosis revenue to imetelstat in due time.

Geron, which has found a development partner in Johnson & Johnson (JNJ -0.11%), has demonstrated immense success with imetelstat in early stage trials in myelofibrosis. Jakafi, the only approved treatment for MF, doesn't generate partial or complete responses. In trials its task was merely to lessen symptoms associated with the disease, such as anemia and enlarged spleen. Imetelstat actually generated partial and complete responses for MF patients, which is something we've never seen before. This data is why Johnson & Johnson was more than willing to give Geron $35 million up-front in 2014 and dangle $900 million in additional milestones on the vine for Geron.

Incyte does have a very extensive list of immunotherapies and proof-of-concept therapies in development beyond Jakafi, as well as bacritinib as an experimental co-developed therapy for rheumatoid arthritis in later-stage studies, so it's not as if all hope is lost. However, Incyte's primary revenue stream could be in jeopardy within a few years. Until we see some meaningful advancement in Incyte's development portfolio, I'm inclined to suggest investors keep to the sidelines.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Incyte Corporation Stock Quote
Incyte Corporation
$68.75 (3.17%) $2.11
Johnson & Johnson Stock Quote
Johnson & Johnson
$163.19 (-0.11%) $0.17
Geron Corporation Stock Quote
Geron Corporation
$2.38 (1.92%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.